Concepedia

Bruna Alves Fenerich

BA

Statistics

Publications

6

Citations

159

H-Index

6

Active since

2016

Affiliations

Universidade de São Paulo(Current)

Oregon Health & Science University

Clinics Hospital of Ribeirão Preto

Howard Hughes Medical Institute

Universidade de Ribeirão Preto

Bruna Alves Fenerich is an author at Universidade de São Paulo specializing in oncology, cancer cell signaling, and molecular oncology.

ORCID

Publications per year

2016–2021

6

Publications

6

IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells

Ana Paula Nunes Rodrigues Alves, Jaqueline Cristina Fernandes, Bruna Alves Fenerich et al. · Cancer Letters · 2019 · 46 citations

, , +17

NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells

Bruna Alves Fenerich, Jaqueline Cristina Fernandes, Ana Paula Nunes Rodrigues Alves et al. · Signal Transduction and Targeted Therapy · 2020 · 33 citations · Full text

, , +17

Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms

João Agostinho Machado‐Neto, Bruna Alves Fenerich, Renata Scopim‐Ribeiro et al. · Cell Death and Disease · 2018 · 31 citations · Full text

, , +17

IRS1/β‐Catenin Axis Is Activated and Induces MYC Expression in Acute Lymphoblastic Leukemia Cells

Jaqueline Cristina Fernandes, Ana Paula Nunes Rodrigues Alves, João Agostinho Machado‐Neto et al. · Journal of Cellular Biochemistry · 2016 · 24 citations · Full text

, , +17

NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia

Renata Scopim‐Ribeiro, João Agostinho Machado‐Neto, Christopher A. Eide et al. · Investigational New Drugs · 2021 · 13 citations

, , +6

1–5 of 6